ClinVar Miner

Submissions for variant NM_032638.5(GATA2):c.1024dup (p.Ala342fs)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001214332 SCV001386009 likely pathogenic Lymphedema, primary, with myelodysplasia; Dendritic cell, monocyte, B lymphocyte, and natural killer lymphocyte deficiency 2019-04-26 criteria provided, single submitter clinical testing This sequence change results in a premature translational stop signal in the GATA2 gene (p.Ala342Glyfs*42). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 139 amino acids of the GATA2 protein. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with GATA2-related conditions. This variant disrupts the p.Arg396 amino acid residue in GATA2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 23223431, 22430350, 22533337, 25624456, 21670465, 24077845). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.